Hepatocellular carcinoma with child Pugh-A Cirrhosis treated with stereotactic body radiotherapy

Table 1 Patient characteristics

	Number	Percentage
Gender
Male	32	82%
Female	8	18%
ECOG performance status1
0	21	55%
1	14	37%
2	3	8%
Etiology of hepatocellular carcinoma2
Hepatitis C	17	46%
Alcohol	8	22%
Combination of Hepatitis C/alcohol	8	22%
NASH	4	8%
BCLC Stage
0 (very early)	6	15%
A (early)	10	25%
B (intermediate)	24	60%
Previous treatment
None	34	85%
TACE	6	15%
Number of treated lesions
Single	32	80%
Multiple3	8	20%
Initial MELD score
< 10	31	78%
> 10	9	22%
Median tumor size (range)	3.5 cm	(1.5 to 8.9 cm)
Median gross tumor volume (range)	23 cc	(2.6 to 220.1 cc)
Median planning target volume (range)	67.6 cc	(11.5 to 351 cc)

¹2 patients unknown;

²1 patient with biliary cirrhosis and 1 immunosuppressed;

³7 patients with 2 lesions and 1 with 3 lesions. ECOG: Eastern cooperative oncology group; NASH: Non-alcoholic steatohepatitis; BCLC: Barcelona liver clinic; TACE: Transarterial chemo-embolization; MELD: Model for end stage liver disease.

Table 2 Summary of prospective stereotactic body radiotherapy studies in hepatocellular carcinoma patients with Child Pugh-A cirrhosis

Study	No of lesions	Median dose-fractionation	Median GTV (cc)	Local control	Overall survival	Grade 3+ toxicity	Median follow-up (m)
Mendez-Romero et al[17], 2006	111	5 Gy × 5	22.3	75%	75%, 40%	36%	12.9
				(22 mo)	(1, 2 yr)
Tse et al[24], 2008	21	6 Gy × 6	173	65%	48%	12%	17.6
				(1 yr)	(1 yr)
Lasley et al[25], 2012	39	16 Gy × 3	-	91%	72%	4.60%	33.3
				(2 yr)	(2 yr)
Bujold et al[33], 2013	102	6 Gy × 6	117	87%	55%, 34%	2%	31
				(1 yr)	(1 yr, 2 yr)
Current study	47	9 Gy × 5	23	98%	92%, 60%	None	24
				(2 yr)	(1 yr, 2 yr)

¹Study includes Child Pugh B patients. GTV: Gross tumor volume; cc: Cubic centimeters; Gy: Gray.